Vixarelimab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris). According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Vixarelimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Vixarelimab is expected to reach an annual total of $93 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vixarelimab Overview
Vixarelimab (KPL-716) is under development for the treatment of pruritus, prurigo nodularis, plaque psoriasis (psoriasis vulgaris), lichen simplex chronicus (neurodermatitis), erosive oral lichen planus, atopic dermatitis, idiopathic pulmonary fibrosis, interstitial lung disease, ulcerative colitis and fibrosis. It is a fully human monoclonal antibody targeting single epitope. The drug candidate is administered intravenously and subcutaneously. It acts by targeting oncostatin M receptor beta.
It was also under development for chronic urticaria or hives.
Roche Overview
Roche is a holding company that is involved in the business of offering oncology, immunology, infectious diseases, ophthalmology and neuroscience research services. The company is headquartered in Basel, Basel-Stadt, Switzerland.
The company reported revenues of (Swiss Francs) CHF58,716 million for the fiscal year ended December 2023 (FY2023), a decrease of 7.2% over FY2022. In FY2023, the company’s operating margin was 25.8%, compared to an operating margin of 27.5% in FY2022. In FY2023, the company recorded a net margin of 19.6%, compared to a net margin of 19.6% in FY2022.
For a complete picture of Vixarelimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.